The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

Two studies published in Nature found stem-cell derived products can not only be safely transplanted into the brain, but also ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...